US Pharm. 2015;40(2):5.
Monrovia, Liberia—The first Ebola vaccines have been shipped to Liberia in West Africa. Phase III clinical trials began in February for use in individuals at high risk of contracting the disease, including healthcare personnel, close contacts of patients, and burial workers. The National Institutes of Health helped develop the vaccines, one from GlaxoSmithKline and the other from Merck. Due to the urgency of the current epidemic, the testing process was accelerated, skipping phase II trials. The Ebola outbreak has infected more than 22,000 people in West Africa and is not expected to end before the middle of the year without a sustained effort.
To comment on this article, contact email@example.com.